ST
RPRX

Spot Trading’s Repros Therapeutics Inc. RPRX Stock Holding History

Spot Trading’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,000
Closed -$13K – 4574
2015
Q4 		$13K Hold
11,000
– – ﹤0.01% 3307
2015
Q3 		$82K Buy
+11,000
New +$84.1K ﹤0.01% 3127
2015
Q1 		– Sell
-1,900
Closed -$19K – 4861
2014
Q4 		$19K Sell
1,900
-8,600
-82% -$73.3K ﹤0.01% 3599
2014
Q3 		$104K Buy
+10,500
New +$155K ﹤0.01% 3501
2014
Q2 		– Sell
-19,900
Closed -$353K – 5207
2014
Q1 		$353K Buy
19,900
+17,200
+637% +$333K ﹤0.01% 2809
2013
Q4 		$49K Sell
2,700
-75,900
-97% -$1.43M ﹤0.01% 3504
2013
Q3 		$2.11M Buy
+78,600
New +$1.68M 0.01% 1339

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Spot Trading's RPRX Position: Q1 2016 in Review

Spot Trading sold out of Repros Therapeutics Inc. (RPRX) in Q1 2016, closing a stake of 150 shares.

Spot Trading first reported a position in RPRX in Q3 2013 and held it in 4 quarters. The position peaked at $1.91M in Q3 2013. 53 funds tracked by Wall St. Rank hold RPRX as of Q1 2016.

  • Spot Trading reported no remaining Repros Therapeutics Inc. position as of Q1 2016 after selling out during the quarter.
  • Spot Trading sold 150 Repros Therapeutics Inc. shares in Q1 2016.
  • Spot Trading first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 4 quarters.
  • Spot Trading's Repros Therapeutics Inc. position peaked at $1.91M in Q3 2013.
  • 53 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2016.

Based on Spot Trading's 13F filing for Q1 2016, filed 10 May 2016.